Last Updated: June 25, 2026

Litigation Details for 2BCom, LLC v. TP Link USA Corporation (C.D. Cal. 2020)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in 2BCom, LLC v. TP Link USA Corporation
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for 2BCom, LLC v. TP Link USA Corporation, Case No. 8:20-cv-00708

Last updated: February 4, 2026

Case Overview
2BCom, LLC filed patent infringement claims against TP Link USA Corporation in the U.S. District Court for the Central District of California. The complaint, filed on April 24, 2020, alleges TP Link infringe patents related to wireless communication technology.

Legal Claims
2BCom asserts infringement of multiple patents, primarily U.S. Patent Nos. 9,345,032 and 10,052,024, which cover aspects of wireless networking devices. The plaintiff alleges that TP Link’s routers and wireless access points incorporate technology protected by these patents.

Defendant’s Response
TP Link denied infringement, stating the accused products do not use the patented technology. The defendant also challenged the validity of the patents in question, asserting prior art invalidates the claims.

Motion Practice

  • Summary Judgment Motion: TP Link filed a motion for summary judgment, seeking dismissal of the infringement claims, contending non-infringement and patent invalidity.
  • Markman Hearing: The court held a Markman hearing to interpret patent claim terms. Clarification on claim scope aimed to resolve factual disputes pre-trial.

Key Developments

  • Discovery Phase: The parties exchanged technical documents and conducted depositions. The plaintiff aimed to establish that TP Link’s products incorporate patented technology.
  • Expert Reports: Expert testimonies clarified the technical scope of the patents and potential infringement. TP Link’s experts challenged the originality and patentability of the claims.

Recent Status
As of the latest update (November 2022), the case remains in pre-trial stages. The court denied TP Link’s summary judgment motion in August 2022, allowing the case to proceed to trial. A jury trial date has yet to be set.

Legal Significance
This case exemplifies target patents involving wireless standards and the ongoing litigation landscape around IoT (Internet of Things) devices. It highlights issues of claim interpretation and patent validity challenges frequently seen in patent infringement suits.

Analysis
The case underscores the importance of clear patent claims and robust prior art searches. The court’s claim construction significantly impacts infringement and validity determinations. The dispute also reflects the industry trend of patent enforcement against major manufacturers of consumer electronics.

Implications for Industry

  • Product Design: Companies must evaluate patent landscapes before product launches.
  • Patent Strategy: Patent holders may pursue enforcement to establish bargaining leverage or market dominance.
  • Litigation Risks: Incumbents face costly, protracted patent disputes, influencing R&D and licensing strategies in wireless technology.

Key Takeaways

  • The case remains unresolved, emphasizing the complexities in patent infringement litigation involving wireless technologies.
  • Claim construction plays a critical role in shaping case outcomes.
  • Patent validity challenges are a common defense in infringement suits.
  • Disputes such as this influence industry-wide standards and licensing negotiations.

FAQs

  1. What patents are involved in 2BCom v. TP Link?
    The case involves U.S. Patent Nos. 9,345,032 and 10,052,024, related to wireless communication technology.

  2. Why did TP Link challenge the patents’ validity?
    TP Link argued the patents are invalid due to prior art that the patents failed to disclose or distinguish.

  3. What is the significance of the Markman hearing?
    It interprets the scope of patent claims, which determines infringement and validity issues.

  4. Has the case gone to trial yet?
    As of the latest update, the case is in pre-trial, with no trial date set.

  5. How could this case impact wireless networking industries?
    It exemplifies ongoing patent enforcement efforts, influencing patent strategies, product development, and licensing negotiations.

Sources
[1] PACER, Case No. 8:20-cv-00708 (accessed Nov 2022)
[2] Court Docket and Filings for 2BCom v. TP Link (2020-2022)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.